Metsera (NASDAQ:MTSR) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Metsera (NASDAQ:MTSR) from a hold rating to a sell rating in a research report report published on Tuesday morning.

A number of other equities research analysts also recently weighed in on MTSR. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Metsera in a research report on Wednesday, September 3rd. Bank of America boosted their price objective on shares of Metsera from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Leerink Partnrs raised shares of Metsera to a “strong-buy” rating in a research report on Tuesday, September 9th. Wells Fargo & Company initiated coverage on shares of Metsera in a research report on Friday, June 20th. They set an “overweight” rating and a $65.00 price objective for the company. Finally, Guggenheim boosted their price objective on shares of Metsera from $56.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, June 10th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $58.50.

Metsera Price Performance

MTSR opened at $52.51 on Tuesday. The company has a 50-day moving average of $36.25 and a 200-day moving average of $29.87. Metsera has a 1-year low of $12.30 and a 1-year high of $54.47.

Metsera (NASDAQ:MTSR) last released its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Alphabet Inc. acquired a new position in Metsera during the 1st quarter valued at about $135,059,000. T. Rowe Price Investment Management Inc. acquired a new position in Metsera during the 1st quarter valued at about $78,748,000. Wellington Management Group LLP acquired a new position in Metsera during the 1st quarter valued at about $65,382,000. Alpha Wave Global LP acquired a new position in Metsera during the 1st quarter valued at about $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in Metsera during the 1st quarter valued at about $42,395,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.